Kenji Tamura
- Oncology top 0.2%
- HER2/EGFR in Cancer Research 75
- Cancer Treatment and Pharmacology 36
- PARP inhibition in cancer therapy 21
- Cancer Research top 0.5%
- Breast Cancer Treatment Studies 25
- Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations 41
- Advanced Breast Cancer Therapies 29
-
- Monoclonal and Polyclonal Antibodies Research 30
- Genetics top 1%
-
- Iron and Steelmaking Processes 22
- Co-authors
- Kan YonemoriYasuhiro FujiwaraMasahiro FukuokaMakiko OnoChikako ShimizuTakahiro OchiyaJackie D. WoodHitoshi Tsuda
- Journals
- Nature Communications (2 papers)Journal of Clinical Oncology (37 papers)SHILAP Revista de lepidopterología (2 papers)
- Partner nations
- JapanUnited StatesUnited Kingdom
In The Last Decade
Kenji Tamura
376 papers receiving 11.7k citations
Hit Papers
Peers
Comparison fields: 5 of 161
- Oncology 6.5k
- Cancer Research 2.5k
- Pulmonary and Respiratory Medicine 3.3k
- Radiology, Nuclear Medicine and Imaging 1.7k
- Genetics 606
Countries citing papers authored by Kenji Tamura
This map shows the geographic impact of Kenji Tamura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenji Tamura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenji Tamura more than expected).
Fields of papers citing papers by Kenji Tamura
This network shows the impact of papers produced by Kenji Tamura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenji Tamura. The network helps show where Kenji Tamura may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Kenji Tamura, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2022 | 13 | |
| 3 | 2021 | 1 | |
| 4 | 2021 | 24 | |
| 5 | 2021 | 19 | |
| 6 | 2020 | 3 | |
| 7 | 2020 | 7 | |
| 8 | 2020 | 8 | |
| 9 | Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 studybreakdown → | 2019 | 258 |
| 10 | 2018 | 47 | |
| 11 | 2018 | 23 | |
| 12 | 2018 | 2 | |
| 13 | 2017 | 55 | |
| 14 | 2017 | 36 | |
| 15 | 2017 | 20 | |
| 16 | 2015 | 54 | |
| 17 | Chemotherapy: Phase Two progress and future perspectives | 2012 | 1 |
| 18 | PHOTODEGRADATION OF RHODAMINE B IN AQUEOUS SUSPENSION OF SYNTHETIC ZN-SUBSTITUTED PHYLLOSILICATES | 2012 | 0 |
| 19 | Physico-chemical properties and their variation of amazonian dark earths distributed in middle Amazon basin, Brazil | 2007 | 1 |
| 20 | Survivin inhibition by si-RNA induces apoptosis and increases sensitivity to adriamycin in human lung cancer cells with p53 mutation | 2004 | 12 |
About Kenji Tamura
Kenji Tamura is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 387 papers that have together received 11.9k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (75 papers), Lung Cancer Treatments and Mutations (41 papers), Cancer Treatment and Pharmacology (36 papers), Monoclonal and Polyclonal Antibodies Research (30 papers), Advanced Breast Cancer Therapies (29 papers), Breast Cancer Treatment Studies (25 papers), Iron and Steelmaking Processes (22 papers) and PARP inhibition in cancer therapy (21 papers). The work is most often cited by research in Oncology (6.5k citations), Cancer Research (2.5k citations) and Pulmonary and Respiratory Medicine (3.3k citations). Kenji Tamura has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Kan Yonemori, Yasuhiro Fujiwara, Masahiro Fukuoka, Makiko Ono, Chikako Shimizu, Takahiro Ochiya, Jackie D. Wood, Hitoshi Tsuda, Toshihiko Doi and Yusuke Yoshioka. Their work appears in journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.